Treatment of Paget's Disease of Bone
Bisphosphonates are the mainstay of treatment for Paget's disease of bone, with a single 5 mg intravenous infusion of zoledronic acid being the most effective therapy, providing sustained biochemical remission for up to 6.5 years. 1, 2, 3
When to Treat
Treatment should be reserved for symptomatic patients rather than treating all cases of Paget's disease, as bisphosphonate therapy in asymptomatic patients has been associated with increased fracture rates. 4
Specific Indications for Treatment:
- Bone pain directly attributable to pagetic sites 2, 3
- Joint pain from osteoarthritis adjacent to pagetic bone 3
- Neurological complications including nerve compression syndromes or hearing loss 3, 5
- Planned surgery at an active pagetic site to reduce intraoperative blood loss 3, 6
- Asymptomatic disease at high-risk sites (skull, weight-bearing bones, vertebrae) where progression could lead to complications 6, 7
- Immobilization hypercalcemia in polyostotic disease 6
Diagnostic Workup
Initial Assessment:
- Plain radiographs of affected skeletal regions showing characteristic lytic or sclerotic lesions 2, 3, 5
- Serum total alkaline phosphatase as the first-line biochemical marker 2, 3
- Radionuclide bone scan to determine the full extent of metabolically active disease 2, 3
Monitoring Disease Activity:
- Measure serum alkaline phosphatase at 3-6 months after treatment initiation to assess response 5
- In monostotic disease with normal alkaline phosphatase, specific bone formation/resorption markers may be needed 3
Treatment Recommendations
First-Line Therapy:
Zoledronic acid 5 mg as a single intravenous infusion is the treatment of choice, achieving:
- Normalization of serum alkaline phosphatase in 89% of patients 6
- Sustained biochemical remission lasting up to 6.5 years 8
- Superior efficacy compared to all other bisphosphonates 1, 2
Alternative Bisphosphonate Options (if zoledronic acid contraindicated):
Listed in order of potency:
- Oral alendronate or risedronate for patients who cannot receive IV therapy 3, 6
- IV pamidronate (15-60 mg) as second-line IV option 9, 6
- Etidronate and tiludronate are less potent, second-line choices 6
Renal Considerations:
Bisphosphonate dosing must be adjusted based on kidney function 9:
- Zoledronic acid: Dose reduction required if GFR <60 mL/min/1.73 m²; avoid if GFR <30 mL/min/1.73 m² 9
- Pamidronate: Avoid if GFR <30 mL/min/1.73 m² 9
- Risedronate: Contraindicated if GFR <30 mL/min/1.73 m² 9
- Etidronate: Reduce dose in mild renal impairment; avoid in moderate-severe impairment 9
Essential Pre-Treatment Measures
Correct vitamin D deficiency and ensure adequate calcium intake before initiating bisphosphonate therapy to prevent hypocalcemia, particularly with potent IV bisphosphonates. 9, 6
- Target 25(OH)D level >32 ng/mL 9
- Calcium intake 1,000-1,200 mg/day 9
- Vitamin D intake 600-800 IU/day 9
Important Safety Considerations
Acute Phase Reaction:
- Fever and flu-like symptoms may occur with first dose of IV nitrogen-containing bisphosphonates, primarily in treatment-naïve patients 6
Osteonecrosis of the Jaw (ONJ):
- Complete dental work before starting bisphosphonates and allow adequate healing time 9
- Incidence is very rare (<1 per 100,000 person-years) with osteoporosis dosing 9
- Risk increases with recent dental surgery or extraction 9
Oral Bisphosphonate Administration:
- Take with full glass of water on empty stomach 9
- Remain upright for at least 30 minutes 9
- Do not eat or drink for at least 30 minutes after administration 9
- May cause esophageal irritation and dyspepsia 9, 6
Treatment Strategy
A "treat-to-symptom" approach is recommended over a "treat-to-target" strategy aimed at normalizing alkaline phosphatase in all patients. 2 The primary goal is relieving bone pain and preventing complications rather than achieving biochemical normalization in asymptomatic individuals. 4, 2